LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Home・Aandelen Lijst・Celsion Corp

Celsion Corp

Gesloten

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken
By Trading Economics
Werknemers	25

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-9.9M 938K
Vorige openingsprijs	0
Vorige sluitingsprijs	0

Celsion Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 nov 2025, 21:06 UTC

Belangrijke Marktbewegers

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 nov 2025, 18:10 UTC

Winsten

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 nov 2025, 13:10 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 12:00 UTC

Winsten

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 nov 2025, 10:30 UTC

Winsten

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 nov 2025, 03:50 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Winsten

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Winsten

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Winsten

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Marktinformatie

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Winsten

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Marktinformatie

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Marktinformatie

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Winsten

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Winsten

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Marktinformatie

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Marktinformatie

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Celsion Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Celsion Corp - Dist in de afgelopen 3 maanden.

Financieel

Over Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.